Stereochemistry at the forefront in the design and discovery of novel anti-tuberculosis agents

Current Topics in Medicinal Chemistry

Volumn 11, Issue 7, 2011, Pages 810-818

  Huang, Qingqing ^a   He, Rong ^a   Kozikowski, Alan P ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Anti tuberculosis agents; Chiral drugs; Stereochemistry

Indexed keywords

1 (6 BROMO 2 METHOXY 3 QUINOLINYL) 4 DIMETHYLAMINO 2 (1 NAPHTHYL) 1 PHENYL 2 BUTANOL; 12 OXOCALANOLIDE A; 2,3 DIHYDRO 2 METHYL 6 NITRO 2 [4 [4 (4 TRIFLUOROMETHOXYPHENOXY) 1 PIPERIDINYL]PHENOXYMETHYL]IMIDAZO[2,1 B]OXAZOLE; 6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; BROMOPHYCOLIDE S; BROMOPHYCOLIDE U; CALANOLIDE A; CALANOLIDE B; CALLICARPIC ACID B; CGI 17341; CORALLOLIDE B; DA 7157; DA 7218; ERYTHROPHLOIN C; ETHAMBUTOL; HYMENIDIN; ISARIOTIN F; ISONIAZID; MONOBROMOISOPHAKELLIN; MOXIFLOXACIN; NATURAL PRODUCT; PYRAZINAMIDE; RIFALAZIL; RIFAMPICIN; STREPTOMYCIN; SUBEROSOL B; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ASYMMETRIC SYNTHESIS; CHIRALITY; DRUG DESIGN; DRUG DEVELOPMENT; DRUG HALF LIFE; DRUG MECHANISM; DRUG STRUCTURE; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; HIGH THROUGHPUT SCREENING; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; REVIEW; STEREOCHEMISTRY; TUBERCULOSIS;

ANIMALS; ANTITUBERCULAR AGENTS; BIOLOGICAL PRODUCTS; DRUG DESIGN; DRUG DISCOVERY; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MICE; MYCOBACTERIUM TUBERCULOSIS; RATS; STEREOISOMERISM; WORLD HEALTH;

EID: 79953660738     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802611795165205     Document Type: Review

References (78)

1. Agranat, I.; Caner, H.; Caldwell, J. Putting chirality to work: the strategy of chiral switches. Nat. Rev. Drug Discov., 2002, 1, 753-768.
2. Caldwell, J. The importance of stereochemistry in drug action and disposition. J. Clin. Pharmacol., 1992, 32, 925-929.
3. Ariens, E. J. Stereochemistry, a basis for sophisticated nonsense in pharmacokinetics and clinical pharmacology. Eur. J. Clin. Pharmacol., 1984, 26, 663-668.
4. Hutt, A. J.; O'Grady, J. Drug chirality: a consideration of the significance of the stereochemistry of antimicrobial agents. J. Antimi-crob. Chemother., 1996, 37, 7-32.
5. Sui, J. J.; Zhang, J. H.; Ching, C. B.; Chen, W. N. Expanding pro-teomics into the analysis of chiral drugs. Mol. Biosyst., 2009, 5, 603-608.
6. Ruffolo, R. R., Jr.; Messick, K. Effects of dopamine, (+/-)-dobutamine and the (+)- and (-)-enantiomers of dobutamine on cardiac function in pithed rats. J. Pharmacol. Exp. Ther., 1985, 235, 558-565.
7. Froimowitz, M.; Cody, V. Absolute configurations and conformations of the opioid agonist and antagonist enantiomers of picenadol. Chirality, 1995, 7, 518-525.
8. Caldwell, J. Do single enantiomers have something special to offer? Hum. Psychopharmacol., 2001, 16, S67-S71.
9. Anon. Thalidomide - A Second Chance? - programme summary. BBC, 2004. http://www.bbc.co.uk/science/horizon/2004/thalidomide.shtml
10. Melchert, M.; List, A. The thalidomide saga. Int. J. Biochem. Cell Biol., 2007, 39, 1489-1499.
11. Holmstedt, B. The use of enantiomers in biological studies: an historical review. In Chirality and Biological Activity, Holmstedt, B., Frank, H.; Testa, B.; Eds.; Alan R Liss: New York, 1990; pp. 1-14.
12. FDA policy statement for the development of new stereoisomeric drugs. Washington, DC, May 1992.
13. Global Tuberculosis Control: a short update to the 2009 report; WHO Library Cataloguing-in-Publication Data: World Health Organization: Geneva, Switzerland, 2009.
14. Godreuil, S. Pulmonary Tuberculosis and Mycobacterium Tuberculosis: Modern Molecular Epidemiology And Perspectives. In Encyclopedia of Infectious Diseases: Modern Methodologies, Ti-bayrenc, M.; Eds.; John Wiley & Son USA, 2007; pp. 1-30.
15. Barrera, L. The basics of clinical bacteriology. In: Tuberculosis 2007 From Basic Science to Patient Care, Palomino, J. C.; Leão, S. C.; Ritacco, V.; Eds.; 2007; pp. 93-112.
16. Faustini, A.; Hall, A. J.; Perucci, C. A. Risk factors for multidrug resistant tuberculosis in Europe: a systematic review. Thorax, 2006, 61, 158-163.
17. Fraser, A.; Paul, M.; Attamna, A.; Leibovici, L. Treatment of latent tuberculosis in persons at risk for multidrug-resistant tuberculosis: systematic review. Int. J. Tubercul. Lung Dis., 2006, 10, 19-23.
18. Nuermberger, E.; Grosset, J. Pharmacokinetic and pharmacody-namic issues in the treatment of mycobacterial infections. Eur. J. Clin. Microbiol. Infect. Dis., 2004, 23, 243-255.
19. Floss, H. G.; Yu, T. W. Rifamycin-mode of action, resistance, and biosynthesis. Chem. Rev., 2005, 105, 621-632.
20. Rabussay, D.; Zillig, W. A rifampicin resistent rna-polymerase from E. coli altered in the beta-subunit. FEBS Lett., 1969, 5, 104-106.
21. Heil, A.; Zillig, W. Reconstitution of bacterial DNA-dependent RNA-polymerase from isolated subunits as a tool for the elucidation of the role of the subunits in transcription. FEBS Lett., 1970, 11, 165-168.
22. Wehrli, W. H.J.; Wunderli, W. Interaction between Rifampicin and DNA-dependent RNA Polymerase of E. coli. In: RNA polymerase, Losick, R. C., M.; Eds.; Cold Spring Harbor Laboratory: Cold Spring Harbor, NY, 1976; p. 397.
23. Naryshkina, T.; Mustaev, A.; Darst, S. A.; Severinov, K. The beta ' subunit of Escherichia coli RNA polymerase is not required for interaction with initiating nucleotide but is necessary for interaction with rifampicin. J. Biol. Chem., 2001, 276, 13308-13313.
24. Sensi, P. History of the development of rifampin. Rev. Infect. Dis., 1983, 5 (Suppl 3), S402-406.
25. Thomas, J. P.; Baughn, C. O.; Wilkinson, R. G.; Shepherd, R. G. A new synthetic compound with antituberculous activity in mice: eth-ambutol (dextro-2,2'-(ethylenediimino)-di-l-butanol). Am. Rev. Respir. Dis., 1961, 83, 891-893.
26. Yendapally, R.; Lee, R. E. Design, synthesis, and evaluation of novel ethambutol analogues. Bioorg. Med. Chem. Lett., 2008, 18, 1607-1611.
27. Forbes, M.; Kuck, N. A.; Peets, E. A. Mode of action of ethambu-tol. J. Bacteriol., 1962, 84, 1099-1103.
28. Alderwick, L. J.; Seidel, M.; Sahm, H.; Besra, G. S.; Eggeling, L. Identification of a novel arabinofuranosyltransferase (AftA) involved in cell wall arabinan biosynthesis in Mycobacterium tuberculosis. J Biol Chem., 2006, 281, 15653-15661.
29. Shepherd, R. G.; Baughn, C.; Cantrall, M. L.; Goodstein, B.; Thomas, J. P.; Wilkinson, R. G. Structure-activity studies leading to ethambutol, a new type of antituberculous compound. Ann. N. Y. Acad. Sci., 1966, 135, 686-710.
30. Comroe, J. H., Jr. Pay dirt: the story of streptomycin. Part I. From Waksman to Waksman. Am. Rev. Respir. Dis., 1978, 117, 773-781.
31. Viljoen, D. L.; Sellars, S. L.; Beighton, P. Familial aggregation of streptomycin ototoxicity: autosomal dominant inheritance? J. Med. Genet., 1983, 20, 357-360.
32. Vicens, Q.; Westhof, E. RNA as a drug target: the case of amino-glycosides. ChemBioChem, 2003, 4, 1018-1023.
33. Tenson, T.; Mankin, A. Antibiotics and the ribosome. Mol. Micro-biol., 2006, 59, 1664-1677.
34. Carr, J. F.; Hamburg, D. M.; Gregory, S. T.; Limbach, P. A.; Dahl-berg, A. E. Effects of streptomycin resistance mutations on post-translational modification of ribosomal protein S12. J. Bacteriol., 2006, 188, 2020-2023.
35. Newman, D. J.; Cragg, G. M. Natural products as sources of new drugs over the last 25 years. J. Nat. Prod., 2007, 70, 461-477.
36. Feher, M.; Schmidt, J. M. Property distributions: differences between drugs, natural products, and molecules from combinatorial chemistry. J. Chem. Inf. Comput. Sci., 2003, 43, 218-227.
37. Lin, A. S.; Stout, E. P.; Prudhomme, J.; Le Roch, K.; Fairchild, C. R.; Franzblau, S. G.; Aalbersberg, W.; Hay, M. E.; Kubanek, J. Bioactive bromophycolides R-U from the Fijian red alga Callophycus serratus. J. Nat. Prod., 2010, 73, 275-278.
38. Vera, B.; Vicente, J.; Rodriguez, A. D. Isolation and structural elucidation of euryjanicins B-D, proline-containing cycloheptapep-tides from the Caribbean marine sponge Prosuberites laughlini. J. Nat. Prod., 2009, 72, 1555-1562.
39. Vicente, J.; Vera, B.; Rodriguez, A. D.; Rodriguez-Escudero, I.; Raptis, R. G., Euryjanicin A: A new cycloheptapeptide from the caribbean marine sponge Prosuberites laughlini. Tetrahedron Lett., 2009, 50, 4571-4574.
40. Ospina, C. A.; Rodriguez, A. D. Corallolides A and B: bioactive diterpenes featuring a novel carbon skeleton. Org. Lett., 2009, 11, 3786-3789.
41. Bunyapaiboonsri, T.; Yoiprommarat, S.; Intereya, K.; Rachtawee, P.; Hywel-Jones, N. L.; Isaka, M. Isariotins E and F, spirocyclic and bicyclic hemiacetals from the entomopathogenic fungus Isaria tenuipes BCC 12625. J. Nat. Prod., 2009, 72, 756-759.
42. Yang, P. S.; Cheng, M. J.; Peng, C. F.; Chen, J. J.; Chen, I. S. En-diandric acid analogues from the roots of Beilschmiedia erythro-phloia. J. Nat. Prod., 2009, 72, 53-58.
43. Chen, J. J.; Wu, H. M.; Peng, C. F.; Chen, I. S.; Chu, S.D. seco-Abietane diterpenoids, a phenylethanoid derivative, and antituber-cular constituents from Callicarpa pilosissima. J. Nat. Prod., 2009, 72, 223-228.
44. Copp, B. R.; Pearce, A. N. Natural product growth inhibitors of Mycobacterium tuberculosis. Nat. Prod. Rep., 2007, 24, 278-297.
45. Currens, M. J.; Gulakowski, R. J.; Mariner, J. M.; Moran, R. A.; Buckheit, R. W., Jr.; Gustafson, K. R.; McMahon, J. B.; Boyd, M. R. Antiviral activity and mechanism of action of calanolide A against the human immunodeficiency virus type-1. J. Pharmacol. Exp. Ther., 1996, 279, 645-651.
46. Xu, Z. Q.; Barrow, W. W.; Suling, W. J.; Westbrook, L.; Barrow, E.; Lin, Y. M.; Flavin, M. T. Anti-HIV natural product (+)-calanolide A is active against both drug-susceptible and drug-resistant strains of Mycobacterium tuberculosis. Bioorg. Med. Chem., 2004, 12, 1199-1207.
47. Xu, Z. Q.; Flavin, M. T.; Jenta, T. R. Calanolides, the naturally occurring anti-HIV agents. Curr. Opin. Drug Discov. Dev., 2000, 3, 155-166.
48. Woldemichael, G. M.; Gutierrez-Lugo, M. T.; Franzblau, S. G.; Wang, Y.; Suarez, E.; Timmermann, B. N. Mycobacterium tuberculosis growth inhibition by constituents of Sapium haematospermum. J. Nat. Prod., 2004, 67, 598-603.
49. Chumkaew, P.; Karalai, C.; Ponglimanont, C.; Chantrapromma, K. Antimycobacterial activity of phorbol esters from the fruits of Sapium indicum. J. Nat. Prod., 2003, 66, 540-543.
50. Wehrli, W. Ansamycins. Chemistry, biosynthesis and biological activity. Top. Curr. Chem., 1977, 72, 21-49.
51. Meilhac, M.; Tysper, Z.; Chambon, P. Animal DNA-dependent RNA polymerases. 4. Studies on inhibition by rifamycin derivatives. Eur. J. Biochem., 1972, 28, 291-300.
52. Dietze, R.; Teixeira, L.; Rocha, L. M.; Palaci, M.; Johnson, J. L.; Wells, C.; Rose, L.; Eisenach, K.; Ellner, J. J. Safety and bactericidal activity of rifalazil in patients with pulmonary tuberculosis. Antimicrob. Agents Chemother., 2001, 45, 1972-1976.
53. Hirata, T.; Saito, H.; Tomioka, H.; Sato, K.; Jidoi, J.; Hosoe, K.; Hidaka, T. In vitro and in vivo activities of the benzoxazinorifamy-cin KRM-1648 against Mycobacterium tuberculosis. Antimicrob. Agents Chemother., 1995, 39, 2295-2303.
54. Williams, D. L.; Spring, L.; Collins, L.; Miller, L. P.; Heifets, L. B.; Gangadharam, P. R.; Gillis, T. P. Contribution of rpoB mutations to development of rifamycin cross-resistance in Mycobacte-rium tuberculosis. Antimicrob. Agents Chemother., 1998, 42, 1853-1857.
55. Klemens, S. P.; Cynamon, M. H. Activity of KRM-1648 in combination with isoniazid against Mycobacterium tuberculosis in a mur-ine model. Antimicrob. Agents Chemother., 1996, 40, 298-301.
56. Mae, T.; Hosoe, K.; Yamamoto, T.; Hidaka, T.; Ohashi, T.; Klee-man, J. M.; Adams, P. E. Effect of a new rifamycin derivative, rifalazil, on liver microsomal enzyme induction in rat and dog. Xeno-biotica, 1998, 28, 759-766.
57. Shandil, R. K.; Jayaram, R.; Kaur, P.; Gaonkar, S.; Suresh, B. L.; Mahesh, B. N.; Jayashree, R.; Nandi, V.; Bharath, S.; Balasubra-manian, V. Moxifloxacin, ofloxacin, sparfloxacin, and ciproflox-acin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. Antimicrob. Agents Chemother., 2007, 51, 576-582.
58. Drlica, K.; Zhao, X. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol. Mol. Biol. Rev., 1997, 61, 377-392.
59. Vera-Cabrera, L.; Gonzalez, E.; Rendon, A.; Ocampo-Candiani, J.; Welsh, O.; Velazquez-Moreno, V. M.; Choi, S. H.; Molina-Torres, C. In vitro activities of DA-7157 and DA-7218 against Mycobacte-rium tuberculosis and Nocardia brasiliensis. Antimicrob. Agents Chemother., 2006, 50, 3170-3172.
60. Shinabarger, D. Mechanism of action of the oxazolidinone antibacterial agents. Expert. Opin. Investig. Drugs, 1999, 8, 1195-1202.
61. Barry, C. E., 3rd; Boshoff, H. I.; Dowd, C. S. Prospects for clinical introduction of nitroimidazole antibiotics for the treatment of tuberculosis. Curr. Pharm. Des., 2004, 10, 3239-3262.
62. Stover, C. K.; Warrener, P.; VanDevanter, D. R.; Sherman, D. R.; Arain, T. M.; Langhorne, M. H.; Anderson, S. W.; Towell, J. A.; Yuan, Y.; McMurray, D. N.; Kreiswirth, B. N.; Barry, C. E.; Baker, W. R. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature, 2000, 405, 962-966.
63. 3rd. PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release. Science, 2008, 322, 1392-1395.
64. Manjunatha, U.; Boshoff, H. I.; Barry, C. E. The mechanism of action of PA-824: Novel insights from transcriptional profiling. Commun. Integr. Biol., 2009, 2, 215-218.
65. de Jonge, M. R.; Koymans, L. H.; Guillemont, J. E.; Koul, A.; Andries, K. A computational model of the inhibition of Mycobacte-rium tuberculosis ATPase by a new drug candidate R207910. Proteins, 2007, 67, 971-980.
66. Andries, K.; Verhasselt, P.; Guillemont, J.; Gohlmann, H. W.; Neefs, J. M.; Winkler, H.; Van Gestel, J.; Timmerman, P.; Zhu, M.; Lee, E.; Williams, P.; de Chaffoy, D.; Huitric, E.; Hoffner, S.; Cambau, E.; Truffot-Pernot, C.; Lounis, N.; Jarlier, V. A diarylqui-noline drug active on the ATP synthase of Mycobacterium tuberculosis. Science, 2005, 307, 223-227.
67. Kamel, H. N.; Kim, Y. B.; Rimoldi, J. M.; Fronczek, F. R.; Ferreira, D.; Slattery, M. Scalarane sesterterpenoids: semisynthesis and biological activity. J. Nat. Prod., 2009, 72, 1492-1496.
68. Nagarajan, K. S.; Rajappa, S.; Shenoy, S. J.; Costa-Pereira, R. Nitroimidazoles XXI 2,3-dihydro-6-nitroimidazo [2,1-b] oxa-zoles with antitubercular activity. Eur. J. Med. Chem., 1989, 24, 631-633.
69. Sasaki, H.; Haraguchi, Y.; Itotani, M.; Kuroda, H.; Hashizume, H.; Tomishige, T.; Kawasaki, M.; Matsumoto, M.; Komatsu, M.; Tsubouchi, H. Synthesis and antituberculosis activity of a novel series of optically active 6-nitro-2,3-dihydroimidazo[2,1-b]oxazoles. J. Med. Chem., 2006, 49, 7854-7860.
70. Matsumoto, M.; Hashizume, H.; Tomishige, T.; Kawasaki, M.; Tsubouchi, H.; Sasaki, H.; Shimokawa, Y.; Komatsu, M. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med., 2006, 3, 2131-2144.
71. Kim, P.; Zhang, L.; Manjunatha, U. H.; Singh, R.; Patel, S.; Jiricek, J.; Keller, T. H.; Boshoff, H. I.; Barry, C. E.; Dowd, C. S. Structure-activity relationships of antitubercular nitroimidazoles. 1. Structural features associated with aerobic and anaerobic activities of 4- and 5-nitroimidazoles. J. Med. Chem., 2009, 52, 1317-1328.
72. Kim, P.; Kang, S.; Boshoff, H. I.; Jiricek, J.; Collins, M.; Singh, R.; Manjunatha, U. H.; Niyomrattanakit, P.; Zhang, L.; Goodwin, M.; Dick, T.; Keller, T. H.; Dowd, C. S.; Barry, C. E. Structure-activity relationships of antitubercular nitroimidazoles. 2. Determinants of aerobic activity and quantitative structure-activity relationships. J. Med. Chem., 2009, 52, 1329-1344.
73. Sutherland, H. S.; Blaser, A.; Kmentova, I.; Franzblau, S. G.; Wan, B.; Wang, Y.; Ma, Z.; Palmer, B. D.; Denny, W. A.; Thompson, A. M. Synthesis and structure-activity relationships of antitubercular 2-nitroimidazooxazines bearing heterocyclic side chains. J. Med. Chem., 2010, 53, 855-866.
74. Palmer, B. D.; Thompson, A. M.; Sutherland, H. S.; Blaser, A.; Kmentova, I.; Franzblau, S. G.; Wan, B.; Wang, Y.; Ma, Z.; Denny, W. A. Synthesis and structure-activity studies of biphenyl analogues of the tuberculosis drug (6S)-2-nitro-6-{[4- (trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2, 1- b][1,3]oxazine (PA-824). J. Med. Chem., 2010, 53, 282-294.
75. Thompson, A. M.; Blaser, A.; Anderson, R. F.; Shinde, S. S.; Franzblau, S. G.; Ma, Z.; Denny, W. A.; Palmer, B. D. Synthesis, reduction potentials, and antitubercular activity of ring A/B ana logues of the bioreductive drug (6S)-2-nitro-6-{[4- (trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2, 1- b][1,3]oxazine (PA-824). J. Med. Chem., 2009, 52, 637-645.
76. Quinoline derivatives and their use as mycobacterial inhibihtors. WO2004011436, 2004.
77. Koul, A.; Dendouga, N.; Vergauwen, K.; Molenberghs, B.; Vranckx, L.; Willebrords, R.; Ristic, Z.; Lill, H.; Dorange, I.; Guillemont, J.; Bald, D.; Andries, K. Diarylquinolines target subunit c of mycobacterial ATP synthase. Nat. Chem. Biol., 2007, 3, 323-324.
78. Upadhayaya, R. S.; Vandavasi, J. K.; Vasireddy, N. R.; Sharma, V.; Dixit, S. S.; Chattopadhyaya, J. Design, synthesis, biological evaluation and molecular modelling studies of novel quinoline derivatives against Mycobacterium tuberculosis. Bioorg. Med. Chem., 2009, 17, 2830-2841.